Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Scyx7158

Research Leaders

6 sponsors active, led by Population Health Research Institute

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 3 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00123916Phase 3Completed

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

NCT01533961Phase 1CompletedPrimary

Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158

Showing all 2 trials

Research Network

Common Treatments

  • Scyx71581
  • Benznidazole1

Active Sponsors

  • Population Health Research Institute1
  • Drugs for Neglected Diseases1
  • University of Sao Paulo1
  • World Health Organization1
  • Canadian Institutes of Health Research (CIHR)1

Top Investigators

Related Conditions

  • Trypanosomiasis African1
  • Heart Disease1
  • Chagas Disease1
  • Parasitic Diseases1
  • Protozoan Infections1

Activity Timeline